👀 Ones to watch: Undervalued stocks to buy before they report Q3 earningsSee Undervalued Stocks

Novartis AG ADR (NVS)

NYSE
Currency in USD
116.22
-0.08(-0.07%)
Closed
After Hours
115.67-0.56(-0.48%)
NVS Scorecard
Full Analysis
Management has been aggressively buying back shares
Earnings results expected in 13 days
Fair Value
Day's Range
115.80116.92
52 wk Range
92.19120.92
Prev. Close
116.3
Open
116.03
Day's Range
115.8-116.92
52 wk Range
92.19-120.92
Volume
773,584
Average Volume (3m)
1,119,879
1-Year Change
20.01%
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
NVS Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
116.70
Upside
+0.41%
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 28 consecutive years
Show more

Novartis ADR Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Employees
76057

Compare NVS to Peers and Sector

Metrics to compare
NVS
Peers
Sector
Relationship
P/E Ratio
23.4x23.7x−0.6x
PEG Ratio
0.200.010.00
Price/Book
5.7x1.9x2.6x
Price / LTM Sales
4.8x3.3x3.2x
Upside (Analyst Target)
3.3%24.2%49.1%
Fair Value Upside
Unlock10.9%7.2%Unlock

People Also Watch

43.83
HSBC
-1.19%
39.36
RHHBY
+0.49%
24.250
ASTS
-3.46%
145.79
RGLD
+2.44%
15.690
GFI
+0.58%

FAQ

What Is the Novartis ADR (NVS) Stock Price Today?

The Novartis ADR stock price today is 116.22

What Stock Exchange Does Novartis ADR Trade On?

Novartis ADR is listed and trades on the NYSE stock exchange.

What Is the Stock Symbol for Novartis ADR?

The stock symbol for Novartis ADR is "NVS."

Does Novartis ADR Pay Dividends? What’s The Current Dividend Yield?

The dividend yield is 2.09%.

What Is the Novartis ADR Market Cap?

As of today, Novartis ADR market cap is 236.26B.

What is Novartis ADR Earnings Per Share?

The Novartis ADR EPS is 7.90.

What Is the Next Novartis ADR Earnings Date?

Novartis ADR will release its next earnings report on 29 Oct 2024.

From a Technical Analysis Perspective, Is NVS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.